{"name":"Ya-Wei Xu","slug":"ya-wei-xu","ticker":"","exchange":"","domain":"","description":"Ya-Wei Xu is a biotechnology company focused on developing novel diagnostic tools and biomarkers for cardiovascular diseases. The company's pipeline includes several phase 2 studies aimed at improving the detection and management of conditions such as acute myocardial infarction.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE53TllqdWt4ZkRWaDNwcHVzakdMSlNGdDkxeWtqcmRTRHltZk1hYW9rZnh3dVZNWkhuU0ZOZ1VWdzNURElMaHpubjJDM1pOS3ZCaFB4REo1VkY0WWlQLTlJ?oc=5","date":"2025-08-15","type":"trial","source":"Nature","summary":"Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial - Nature","headline":"Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5mUTVmcmpYbi1SQlJLbUt6Z3RoUWJnWW1SaUlNZ2xTaE13SE13VnVWbnRnZGNMaWRlazZ5ZDh4NmZtaEpxa2Q5Uk95RC1LR29LLTA0Q3IzTFpOWVhhSzdz?oc=5","date":"2024-02-14","type":"pipeline","source":"Nature","summary":"Cardiac cell senescence: molecular mechanisms, key proteins and therapeutic targets - Nature","headline":"Cardiac cell senescence: molecular mechanisms, key proteins and therapeutic targets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9TOE9UajY3eVdEVk5YSVI1ejRPbFhac0Y5UzczWTdidjlfN2p3dEd0QWpRakhWQzFXS1h1RDNfd2lodll1QmRJSzdMQ1d2cjNwSlZIV3EzTm12dk5UclVYQzFNamNDLVZNMVB4VU10NGMyUTN4ZXZVUG93R04?oc=5","date":"2022-03-23","type":"trial","source":"American Heart Association Journals","summary":"Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy - American Heart Association Journals","headline":"Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China S","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}